Skip to main content

Table.1 Baseline characteristics of the patients by 5% weight change from baseline

From: Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial

Characteristic

Weight loss ≥ 5%

Stable weight

Weight gain ≥ 5%

P-value

N

1044

2677

1659

 

Age, years

61.3 ± 10.0

61.7 ± 10.0

59.3 ± 9.6

< 0.001

Age > 65 year

391 (37.5%)

1052 (39.3%)

464 (28.0%)

< 0.001

Female, n (%)

397 (38.0%)

843 (31.5%)

489 (29.5%)

< 0.001

Diabetes duration, years

7.5 (2.8, 14.0)

7.1 (2.9, 13.3)

6.9 (2.4, 14.0)

0.43

Glycated hemoglobin, %

8.0 ± 1.1

8.0 ± 1.1

8.1 ± 1.1

0.030

Insulin, n (%)

300 (28.7%)

782 (29.2%)

523 (31.5%)

0.19

Metformin, n (%)

701 (67.1%)

1776 (66.3%)

1085 (65.4%)

0.63

Sulfonylureas, n (%)

445 (42.6%)

1270 (47.4%)

788 (47.5%)

0.019

Thiazolidinediones, n (%)

38 (3.6%)

49 (1.8%)

44 (2.7%)

0.004

Weight at baseline, Kg

84.5 ± 21.0

83.6 ± 18.6

78.5 ± 18.3

< 0.001

BMI at baseline, Kg/m2

30.5 ± 6.3

29.7 ± 5.4

28.4 ± 5.3

< 0.001

Race

   

< 0.001

White

735 (70.4%)

2051 (76.6%)

1123 (67.7%)

 

Asian

232 (22.2%)

479 (17.9%)

378 (22.8%)

 

Black

57 (5.5%)

79 (3.0%)

80 (4.8%)

 

Other

20 (1.9%)

68 (2.5%)

78 (4.7%)

 

Current smoker, n (%)

145 (13.9%)

374 (14.0%)

215 (13.0%)

0.62

Hypertension, n (%)

889 (85.2%)

2279 (85.1%)

1301 (78.4%)

< 0.001

HF history, n (%)

298 (28.5%)

836 (31.2%)

399 (24.1%)

< 0.001

Prior stroke, n (%)

85 (8.1%)

190 (7.1%)

113 (6.8%)

0.40

PAD, n (%)

122 (11.7%)

266 (9.9%)

126 (7.6%)

0.001

Atrial fibrillation, n (%)

95 (9.1%)

190 (7.1%)

91 (5.5%)

0.002

MI (index event), n (%)

794 (76.3%)

1993 (74.7%)

1365 (82.3%)

< 0.001

Unstable angina (index event), n (%)

246 (23.7%)

675 (25.3%)

293 (17.7%)

 

Hemoglobin, g/dl

13.2 ± 1.6

13.6 ± 1.6

13.4 ± 1.5

< 0.001

Anemia, n (%)

312 (30.0%)

623 (23.3%)

433 (26.1%)

< 0.001

eGFR, ml/min/1.73m2

67.5 ± 21.2

71.1 ± 21.1

72.8 ± 21.8

< 0.001

eGFR < 60 ml/min, n (%)

353 (33.8%)

761 (28.4%)

451 (27.2%)

< 0.001

Heart rate, bpm

72.1 ± 11.2

70.8 ± 10.7

71.8 ± 10.7

< 0.001

SBP, mmHg

129.7 ± 17.4

129.9 ± 15.8

127.1 ± 17.3

< 0.001

SBP > 140/90 mmHg, n (%)

238 (22.8%)

545 (20.4%)

297 (17.9%)

0.007

Total cholesterol, mg/dl

146 (123, 148)

149 (126, 178)

143 (122, 173)

0.001

HDL cholesterol, mg/dl

42 (36, 48)

42 (36, 49)

42 (35, 48)

0.11

LDL cholesterol, mg/dl

72 (55, 97)

74 (55, 97)

70 (53, 94)

0.010

Triglycerides, mg/dl

138 (102, 192)

143 (104, 200)

139 (102, 191)

0.12

Antiplatelets at baseline, n (%)

1008 (96.6%)

2600 (97.1%)

1624 (97.9%)

0.10

Beta-blockers at baseline, n (%)

836 (80.1%)

2220 (82.9%)

1355 (81.7%)

0.12

Statins at baseline, n (%)

930 (89.1%)

2402 (89.7%)

1534 (92.5%)

0.003

CCBs at baseline, n (%)

244 (23.4%)

641 (23.9%)

312 (18.8%)

< 0.001

Diuretics at baseline, n (%)

432 (41.4%)

988 (36.9%)

594 (35.8%)

0.010

ACEi or ARB at baseline, n (%)

856 (82.0%)

2227 (83.2%)

1328 (80.0%)

0.033

Randomization to alogliptin

541 (51.8%)

1332 (49.8%)

828 (49.9%)

0.51

  1. BMI, body mass index; PAD, peripheral artery disease; MI, myocardial infarction; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; CCBs, calcium channel blockers; ACEi/ARBs, angiotensin converting enzyme inhibitors/angiotensin receptor blockers